Isis Pharma (ISIS) to Present Data from ISIS-SMNRx Phase 2 at WMS; Offers Update
Tweet Send to a Friend
Isis Pharma (Nasdaq: ISIS) provided an update on its ongoing open-label Phase 2 clinical studies of ISIS-SMNRx in infants and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
